PI3K pathway activation is caused by the presence of a gain of function mutation in the PI3KCA gene, and recently BKM120, a drug that targets the PI3K pathway, was used to treat stage I non‐small cell lung cancer patients with tumors showing PI3K pathway activation. Here, PIK3CA is linked to lung cancer.